CRL

CHARLES RIVER LABORATORIES INTERNATIONAL INC

Healthcare | Mid Cap

$2.22

EPS Forecast

$991.1

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-08-29

CRL’s Second Quarter 2026: A Deliberate Pivot toward AI, Divestitures, and a Cautiously Upbeat Revenue Forecast

In Charles River Laboratories International, Inc. (ticker: CRL), the 2026 Second-Quarter Results unfold as a study in portfolio realignment rather than a single-number triumph. The company posted revenue of $1.00 billion, a 2.7% year-over-year dip, with organic growth of 0.1%. GAAP EPS declined to a loss of $(0.03) per share, while non-GAAP EPS hit $3.02. Management nudged the revenue forecast and non-GAAP EPS consensus higher for 2026, signaling a shift from legacy segments to higher-margin, tech-enabled services. The release also doubles as a portfolio reset—divestitures, stock repurchases, and strategic partnerships all figure prominently as the company leans into AI-enabled workflows and expanded collaborations.

Key quarterly numbers

  • Revenue: $1.00 billion, down 2.7% from $1.03 billion in Q2 2025; organic growth +0.1%
  • GAAP EPS: $(0.03) per diluted share
  • Non-GAAP EPS: $3.02 per diluted share
  • GAAP operating margin: 11.9%; Non-GAAP operating margin: 20.5%
  • Non-GAAP net income: $146.2 million, down 5.0% vs. $154.0 million in Q2 2025
  • Second-quarter divestiture-related impact: a loss totaling $63.7 million, or $1.40 per share
  • Stock repurchase: $100 million in Q2 at an average price of $174 per share

Portfolio actions and strategic moves

The company completed divestitures of European Discovery Services sites and the CDMO and Cell Solutions businesses in May 2026, reshaping the core portfolio as a platform for higher-return growth. Management frames these moves as alignment with a clearer long-term growth trajectory, even as they weigh on near-term GAAP results.

Guidance and outlook

Charles River raised its 2026 guidance for revenue and non-GAAP EPS at the midpoint. The revenue forecast now reflects a higher trajectory, with organic revenue guidance increased by 150 basis points. The EPS consensus for non-GAAP profitability rises by $0.25 at the midpoint. The lift is attributed to better demand in the Discovery and Safety Assessment (DSA) and Manufacturing segments, alongside generally improving demand trends and the company’s ongoing portfolio optimization.

AI, partnerships, and product modernization

Beyond the divestitures, CRL is doubling down on technology-enabled services. The company has joined Eli Lilly’s TuneLab AI/ML platform to provide non-clinical testing expertise that could shorten drug discovery timelines and accelerate R&D modernization efforts. It has also collaborated with Arovella Therapeutics to provide in vitro Next Generation Sequencing (NGS) services, enabled by the PathoQuest acquisition. A renewed emphasis on digital pathology is front and center—a newer, AI-enabled, end-to-end workflow designed to digitize and automate study processes, improve turnaround times, and boost pathologist efficiency.

Margins, operations, and what it means for peers

The quarterly move toward higher non-GAAP margins—driven in part by the CDMO and related divestiture effects—highlights how mix shifts and cost discipline can lift profitability even as reported GAAP results wobble. The margin expansion in the non-GAAP measure, to 20.5% from 22.1% in the prior year’s quarter, underscores the pressure and the payoff of portfolio refinement. For peers in the sector, the message is clear: scale improvements in high-value services paired with AI-enabled workflows can unlock upside even when legacy segments prove volatile. The path ahead may involve more asset-light offerings, partnering for AI-enabled capabilities, and selective divestitures to focus on higher-margin, growth-oriented services.

Takeaways for CRL and its sector peers

CRL’s results emphasize a few durable themes: (1) alignment of portfolio with higher-margin, tech-forward services; (2) meaningful but non-urgent reliance on one-off divestiture impacts on GAAP metrics; (3) a more aggressive tilt toward AI-enabled workflows and external partnerships that could shorten R&D timelines for customers; and (4) a balanced approach to capital allocation, evidenced by the $100 million stock repurchase and ongoing emphasis on shareholder value. For the industry, the combination of clinical services convergence with AI-driven automation could tilt competitive dynamics toward players who can blend execution risk with rapid tech adoption, potentially setting new baselines for revenue forecast revisions and EPS consensus expectations across peers.

About the numbers and the language

As with any earnings release, investors will parse GAAP vs. non-GAAP results, watch for an earnings surprise (or lack thereof) relative to EPS consensus and how the company’s revenue forecast evolves. CRL’s reported figures show a mixed picture—one-off divestiture costs and other non-operating items weigh on GAAP results, while ongoing operations and margin discipline support a constructive longer-term narrative.

Conclusion

Charles River’s Q2 2026 underscores a company actively retooling its engine: shedding lower-margin assets, investing in AI-enabled services, and guiding the top-line higher. If the trajectory holds, CRL could begin to translate its non-GAAP margin resilience and growth in DSA and Manufacturing into a more durable earnings cadence—one that might quietly redraw competitive lines in the lab services arena. The market will be watching whether the portfolio moves translate into sustained revenue growth and whether new partnerships begin to lift the EPS line in a way that makes the lengthy tail of divestitures feel like a well-timed pruning rather than a costly detour.